3 Promising Penny Stocks With Market Caps Over $200M

In the last week, the market has stayed flat, but it is up 15% over the past year with expectations for earnings to grow by 18% per annum over the next few years. Though 'penny stocks' might sound like a relic of past trading days, they continue to offer potential opportunities for growth when backed by strong financials. We'll explore several penny stocks that could pair balance sheet strength with long-term potential, offering investors a chance to uncover hidden value in quality companies.

We're going to check out a few of the best picks from our screener tool.

Hello Group (MOMO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Hello Group Inc. operates mobile-based social and entertainment services in China and internationally, with a market cap of approximately $678 million.

Operations: The company generates revenue from its Internet Information Providers segment, amounting to CN¥10.10 billion.

Market Cap: $677.96M

Hello Group Inc. has demonstrated strong earnings growth, with profits increasing significantly over the past five years and a current net profit margin of 11%. The company trades at a good value compared to peers and has reduced its debt-to-equity ratio from 30.7% to 0.03% in five years, indicating financial prudence. Despite recent revenue declines, Hello Group reported improved net income for the second quarter of 2026 compared to a loss last year. Analysts expect earnings to decline slightly in coming years, but short-term assets comfortably cover liabilities, underscoring financial stability amidst executive changes.

• Click to explore a detailed breakdown of our findings in Hello Group's financial health report.
• Learn about Hello Group's future growth trajectory here.

Nuvation Bio (NUVB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to developing cancer treatment product candidates, with a market cap of $1.76 billion.

Operations: The company's revenue is derived entirely from its oncology development activities, totaling $169.9 million.

Market Cap: $1.76B

Nuvation Bio Inc. remains a speculative investment due to its pre-revenue status, despite having a market cap of US$1.76 billion and recent FDA approval for IBTROZI (taletrectinib) for ROS1+ NSCLC treatment. The company's financials show a net loss of US$62.84 million in Q2 2026, although revenue increased to US$31.69 million from the previous year. Nuvation's management team is experienced, and its short-term assets significantly exceed liabilities, providing some financial cushion. However, the debt-to-equity ratio has risen considerably over five years, indicating potential financial strain if not managed carefully.

• Jump into the full analysis health report here for a deeper understanding of Nuvation Bio.
• Assess Nuvation Bio's future earnings estimates with our detailed growth reports.

Zhihu (ZH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zhihu Inc., with a market cap of $264.76 million, operates an online content community in the People's Republic of China through its subsidiaries.

Operations: The company generates revenue of CN¥2.64 billion from its Internet Information Providers segment.

Market Cap: $264.76M

Zhihu Inc. is navigating the penny stock landscape with a market cap of $264.76 million and revenue of CN¥2.64 billion, though it remains unprofitable with a negative return on equity of -8.12%. The company has reduced its losses by 44.4% annually over five years, suggesting some operational improvement despite recent quarterly earnings showing a net loss of CN¥37.42 million compared to last year's net income. Zhihu's financial stability is underpinned by short-term assets exceeding both short- and long-term liabilities, while recent share buybacks indicate management's confidence in the company's future prospects amidst ongoing challenges.

• Navigate through the intricacies of Zhihu with our comprehensive balance sheet health report here.
• Examine Zhihu's earnings growth report to understand how analysts expect it to perform.

Next Steps

• Click this link to deep-dive into the 320 companies within our US Penny Stocks screener.
• Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com